Scientists as Temporaries

In the past few years, this type of headline has begun to appear more and more frequently Why? In times more economically secure than these-before Gramm-Rudman, the volatile stock market, dramatic takeovers, and increased shareholder awareness-a company set out to do a job, hired staff and hoped to be successful. If, along the way, the company experienced sudden growth, it hired to accommodate the new orders. When business slowed, it laid people off. What companies attempted to do on a large s

Written byIra Litman
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

In times more economically secure than these-before Gramm-Rudman, the volatile stock market, dramatic takeovers, and increased shareholder awareness-a company set out to do a job, hired staff and hoped to be successful. If, along the way, the company experienced sudden growth, it hired to accommodate the new orders. When business slowed, it laid people off. What companies attempted to do on a large scale was respond to market fluctuation.

Traditionally, some companies have earned a less than winning reputation for "luctuating" (hiring and firing) without regard to employees' needs. Often, their gains in financial efficiency were offset by low employee morale, decreased productivity and, because of their reputation, above average recruitment costs when it was necessary to staff up. Their operating capital was proportionately reduced because the more people they generated for unemployment rolls, the greater was their unemployment tax rate.

Other companies, in an effort to foster a paternal ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies